Synamet Plus^®

Levodopa+Carbidopa+Entacapone

Description
Synamet Plus is a combination of Levodopa, Carbidopa and Entacapone for the treatment of Parkinson's disease. Levodopa, the metabolic precursor of dopamine, is converted to dopamine in the brain. Carbidopa is a dopa decarboxylase (DDC) inhibitor which reduces the peripheral metabolism of Levodopa to dopamine, and thus more levodopa is available to the brain. Entacapone is a selective inhibitor of catechol-o-methyltransferase. Given concurrently. entacapone results in greater and more sustained plasma levels of levodopa, leading to greater control of Parkinsonism syndrome.

Indication
Synamet Plus is indicated for the treatment of adult patients with Parkinson's disease. and end-of dose motor fluctuations not stabilized on levodopa/dopa decarboxylase (DDC) inhibitor treatment. Besides, it can be used to substitute (with equivalent strength of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products.

Supply
Synamet Plus Tablet 50/12.5/200 mg: Each box contains 2x10's tablets in ALU-ALU blisted strip.
Synamet Plus Tablet 100/25/200 mg: Each box contains 2x10's tablets in ALU-ALU blisted strip.